MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.740
-0.270 (-13.43%)
At close: Jun 12, 2026, 4:00 PM EDT
1.660
-0.080 (-4.58%)
Pre-market: Jun 15, 2026, 5:15 AM EDT
MetaVia Employees
MetaVia had 8 employees as of December 31, 2025. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,640,625
Market Cap
8.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -1 | -11.11% |
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Bolt Biotherapeutics | 23 |
| BioCardia | 21 |
| Imunon | 20 |
| BioRestorative Therapies | 14 |
| NuCana | 12 |
| Aprea Therapeutics | 8 |
| Intensity Therapeutics | 7 |
MTVA News
- 3 days ago - MetaVia Transcript: Emerging Growth Conference 93 - Transcripts
- 6 days ago - MetaVia Transcript: AGM 2026 - Transcripts
- 6 days ago - MetaVia presents data at ADA supporting DA-1726, vanoglipel - TheFly
- 6 days ago - MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential - PRNewsWire
- 10 days ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PRNewsWire
- 18 days ago - MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations - TheFly
- 18 days ago - MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH - PRNewsWire
- 24 days ago - 3 Penny Stocks to Watch Now, 5/21/26 - TipRanks